custom immunoassays on the meso scale discovery multi-array platform (Meso Scale Diagnostics LLC)
90
Structured Review
Meso Scale Diagnostics LLC
custom immunoassays on the meso scale discovery multi-array platform
Custom Immunoassays On The Meso Scale Discovery Multi Array Platform, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+immunoassays+on+the+meso+scale+discovery+multi-array+platform/meso+scale+discovery++msd++platform/10__1136_slash_annrheumdis___2012___eular__2633-6-5-9
Average 90 stars, based on 1 article reviews
Custom Immunoassays On The Meso Scale Discovery Multi Array Platform, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+immunoassays+on+the+meso+scale+discovery+multi-array+platform/meso+scale+discovery++msd++platform/10__1136_slash_annrheumdis___2012___eular__2633-6-5-9
Average 90 stars, based on 1 article reviews
custom immunoassays on the meso scale discovery multi-array platform - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: FRI0176 Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks as monotherapy in patients with active rheumatoid arthritis despite dmard therapy: 52-week results of clinical, radiographic and pharmacokinetic assessments Article Snippet: Background: Anti-TNF therapy has been grown to a standard therapeutic strategy for rheumatoid arthritis (RA).. To date, we have developed a multi-biomarker disease activity algorithm (MBDA) as a potential index to provide objective biological information about RA activity.. However, the relationship between MBDA and SDAI/CDAI focusing on anti-TNF therapy has not been investigated. |